Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide, affecting 20-30% of adults and 3-10% of children in Western countries. The pathogenesis of NAFLD is considered to be multifactorial and factors such as insulin resistance, intrahepatic fat accumulation, oxidative stress, mitochondrial alterations, and stellate cell activation appear to substantially contribute to the development and progression of the disease. In this Editorial, we highlight some evidence suggesting a close link between NAFLD and growth hormone (GH)-IGF (insulin-like growth factor) axis.
Keywords: GH therapy; IGFs; children; cytokines; fatty liver.